Comparative Pharmacology
Head-to-head clinical analysis: AMANTADINE HYDROCHLORIDE versus FAVLYXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMANTADINE HYDROCHLORIDE versus FAVLYXA.
AMANTADINE HYDROCHLORIDE vs FAVLYXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amantadine hydrochloride is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In Parkinson's disease, it increases dopamine release and inhibits dopamine reuptake, and also acts as an NMDA glutamate receptor antagonist, reducing excitotoxicity.
Acyclic nucleoside phosphonate prodrug that inhibits viral RNA-dependent RNA polymerase (RdRP) by competing with adenosine triphosphate (ATP). It incorporates into nascent viral RNA causing chain termination after incorporation of the first 1-2 nucleotides.
For parkinsonism/drug-induced extrapyramidal symptoms: initial 100 mg twice daily; may increase to 300-400 mg/day in divided doses if needed. For influenza A treatment/prophylaxis in adults: 200 mg once daily or 100 mg twice daily; initiate prophylaxis as early as possible and continue for at least 10 days post-exposure.
200 mg orally twice daily for 10 days.
None Documented
None Documented
Terminal elimination half-life: 10-14 hours in young adults; up to 34 hours in elderly (due to age-related decline in renal function); prolonged in renal impairment (up to 7 days in anuria).
Terminal elimination half-life approximately 5-7 hours in patients with normal renal function; prolonged in renal impairment (up to 24 hours in severe impairment).
Renal: 90% unchanged drug via glomerular filtration and tubular secretion; minor fecal (<5%) and biliary elimination.
Primarily renal excretion of unchanged drug (approx. 85%) with biliary/fecal elimination accounting for the remainder (approx. 15%).
Category C
Category C
Antiviral / Antiparkinsonian
Antiviral